Infection

, Volume 19, Issue 4, pp 289–296 | Cite as

Safety of ciprofloxacin in children: Worldwide clinical experience based on compassionate use. Emphasis on joint evaluation

  • V. Chyský
  • R. Hullmann
  • P. Schacht
  • K. Kapila
  • R. Echols
  • G. Arcieri
Addenda Quinolones In Clinical Use

Summary

Six hundred and thirty four adolescents and children aged three days to 17 years treated with ciprofloxacin on a compassionate basis were analysed for drug safety. 62% of the ciprofloxacin courses were given to patients with respiratory tract infection, primarily those with acute pulmonary exacerbation of cystic fibrosis. The mean daily oral dose was 25.2 mg/kg body weight. The duration of treatment ranged from one to 880 days (mean 22.8 days). Because of the arthropathogenic potential of quinolones in juvenile animals special emphasis was placed on the evaluation of musculoskeletal adverse events. Arthralgia considered by the treating physicians to be related to ciprofloxacin was reported in eight children, all of whom were females. Arthralgia resolved in all children. Some of these children were given subsequent courses of ciprofloxacin with no complaints of arthralgia. Overall, the safety profile of ciprofloxacin in children is not substantially different from that of adults.

Verträglichkeit von Ciprofloxacin bei Kindern unter besonderer Beachtung der Gelenke. Auswertung weltweit dokumentierter Problemfälle

Zusammenfassung

Die Verträglichkeit des Ciprofloxacin nach Anwendung bei 634 Jugendlichen und Kindern im Alter von drei Tagen bis 17 Jahren wurde analysiert. 62% der Behandlungen mit Ciprofloxacin erhielten Patienten mit Atemwegsinfektionen, insbesondere mit akuter pulmonaler Exazerbation der Mukoviszidose. Der Mittelwert der oralen Tagesdosis war 25,2 mg/kg Körpergewicht. Die Therapiedauer variierte zwischen 1 und 880 Tagen (Mittelwert 22,8 Tage). Wegen der gelenkknorpelschädigenden Wirkung der Chinolone bei juvenilen Versuchstieren wurde besondere Aufmerksamkeit der Beurteilung der mit Gelenken verbundenen Nebenerscheinungen gewidmet. Arthralgie, die von den behandelnden Ärzten als Folge der Ciprofloxacin-Behandlung beurteilt wurde, ist bei acht Kindern berichtet worden. Alle waren weiblich. Die Arthralgie verschwand bei allen Kindern. Einige dieser Kinder erhielten nachträgliche Behandlungen mit Ciprofloxacin ohne Auftreten arthralgischer Beschwerden. Generell unterschied sich das Verträglichkeitsprofil bei Kindern nicht wesentlich von dem der Erwachsenen.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ingham, B., Brentuall, D. W., Dale, E. A., Mc Fadzean, V. A. Arthropathy induced by antibacterial fused N-alkyl-4-pyridone-3carboxylic acids. Toxicol. Lit. 1 (1977) 21–26.Google Scholar
  2. 2.
    Schlüter, G. Ciprofloxacin: Review of potential toxicologic effects. Am. J. Med. 82 (Suppl. 4A) (1987) 91–93.Google Scholar
  3. 3.
    Schlüter, G. Ciprofloxacin: Toxicologic evaluation of additional safety data. Am. J. Med. 87 (Suppl. 5A) (1989) 37–39.Google Scholar
  4. 4.
    Hoffmann, K., Deprechins, B.: Joint lesions induced by quinolones — differences between clinical, M. R. I. and post mortem findings. 3rd Internatl. Symposion on New Quinolones, Vancouver, Canada, July 1990, Abstract 461.Google Scholar
  5. 5.
    Deprechins, B., Dab, I., Osteaux, M., Hoffmann, K.: Relevance of magnetic resonance imaging in the evaluation of ciprofloxacin-induced arthropathy in juvenile experimental animals. 3rd Internatl. Symposion on New Quinolones, Vancouver, Canada, July 1990, Abstract 462.Google Scholar
  6. 6.
    Stahlmann, R., Merker, H. J., Hinz, N., Chahoud, I., Webb, J., Heger, W., Neubert, D. Ofloxacin in juvenile non-human primates and rats. Arthropathia and drug plasma concentrations. Arch. Toxicol. 64 (1990) 193–204.Google Scholar
  7. 7.
    Schaad, U. B., Wedgwood, J., Terrier, F., Tschaeppeler, H., Vock, P.: Magnetic resonance imaging (MRI) examination of the knee in children with cystic fibrosis before and after a 3-month course of ciprofloxacin. 30th ICAAC, Atlanta, October 1990, Abstract No. 6.Google Scholar
  8. 8.
    Rumler, W., v. Rohden, L.: Does nalidixic acid produce joint toxicity in childhood? 15th Int. Congress of Chemotherapy, Proceedings 1029–1031, Istambul, July 1987.Google Scholar
  9. 9.
    Schaad, U. B., Wedgwood-Krucko, J. Nalidixic acid in children: retrospective matched controlled study for cartilage toxicity. Infection 15 (1987) 165–168.Google Scholar
  10. 10.
    Arcieri, G. M., Becker, N., Esposito, B., Griffith, E., Heyd, A., Neumann, Ch., O'Brien, B., Schacht, P. Safety of intravenous ciprofloxacin. Am. J. Med. 87 (Suppl. 5A) (1989) 92–97.Google Scholar
  11. 11.
    Schacht, P., Arcieri, G., Hullmann, R. Safety of oral ciprofloxacin. Am. J. Med. 87 (Suppl. 5A) (1989) 98–102.Google Scholar
  12. 12.
    Reiter, Ch., Pfeiffer, M., Hullmann, R. Brief report: Safety of ciprofloxacin based on phase IV studies (Anwendungsbeobachtung) in the Federal Republic of Germany. Am. J. Med. 87 (Suppl. 5A) (1989) 103–106.Google Scholar
  13. 13.
    Kapila, K., Chyský, V., Hullmann, R., Arcieri, G., Schacht, P., Echols, R.: Worldwide clinical experience on safety of ciprofloxacin in children on compassionate use basis. 3rd Internatl. Symp. on New Quinolones, Vancouver, July 1990, Abstract 064.Google Scholar
  14. 14.
    Chyský, V., Kapila, K., Hullmann, R., Arcieri, G., Schacht, P., Echols, R.: Worldwide clinical experience on safety of ciprofloxacin in children on compassionate use basis. 2nd Western Pacific Congress on Infectious Diseases and Chemotherapy, Jomtien-Pattaya, Thailand, December 1990, Program and Abstracts p. 459.Google Scholar
  15. 15.
    Kearns, G. L., Reed, M. D. Clinical pharmacokinetics in infants and children: A reappraisal. Clin. Pharmacokinetics 17 (Suppl. 1) (1989) 29–67.Google Scholar
  16. 16.
    Personal communication Google Scholar
  17. 17.
    Kiess, W., Haas, R., Marget, W. Chloramphenicol-resistantSalmonella tennessee osteomyelitis. Infection 12 (1984) 359.Google Scholar
  18. 18.
    Kuhn, R. J., Kangan, J. F., Palmejar, A. R. Retrospective review of ciprofloxacin for the treatment of acute pulmonary exacerbations in pediatric CF patients. Pediatric Pulmonology (Suppl. 5) (1990) 246.Google Scholar
  19. 19.
    Desmyttere, S., Dab, I., Malfroot, A., Pierard, D., Deprechins, B.: Ciprofloxacin use in children with ciprofloxacin. 3rd Internatl. Symposion on New Quinolones, Vancouver, Canada, July 1990, Book of Abstracts, Abstract 2.Google Scholar
  20. 20.
    Enenkel, S., Bender, S., Posselt, H. G.: Treatment with quinolones of pulmonaryPseudomonas aeruginosa infections in patients with cystic fibrosis. 3rd Internatl. Symposion on New Quinolones, Vancouver, Canada, July 1990, Book of Abstracts, Abstract 359.Google Scholar
  21. 21.
    Baran, D., Dab, I., Pierard, D., Serruis, E.: Prospective open efficacy and safety study of ciprofloxacin in the treatment of cystic fibrosis patients with pulmonary infection. 15th Annual Meeting of the European Working Group for Cystic Fibrosis, Oslo, June 17–20, 1987.Google Scholar
  22. 22.
    Rubio, T. T.: Oral ciprofloxacin in the treatment ofPseudomonas aeruginosa in children with cystic fibrosis. Ciprofloxacin: major advances in intravenous and oral quinolones therapy, Naples, April 28–29, 1989.Google Scholar
  23. 23.
    Rubio, T. T. Ciprofloxacin: comparative data on cystic fibrosis. Am. J. Med. 82 (Suppl. 4A) (1987) 185–188.Google Scholar
  24. 24.
    Rubio, T. T. Ciprofloxacin in the treatment of Pseudomonas infection in children with cystic fibrosis. Diag. Microbiol. Infect. Dis. 13 (1990) 153–155.Google Scholar
  25. 25.
    Rubio, T. T.: Ciprofloxacin in children with cystic fibrosis, clinical and laboratory experience. 2nd Internatl. Symposion on New Quinolones, Geneva, August 25–27, 1988, Abstract No. 229.Google Scholar
  26. 26.
    Scully, B. E., Nakatomi, M., Ores, C., Davidson, S., Neu, H. C. Ciprofloxacin therapy in cystic fibrosis. Am. J. Med. 82 (Suppl. 4A) (1987) 196–201.Google Scholar
  27. 27.
    Schaad, U. B., Wedgwood, J., Kraemer, R. Efficacy and safety in pediatric patients with cystic fibrosis. 2nd Internatl. Symposion on New Quinolones, Geneva, August 25–27, 1988. Rev. Infect. Dis. 11 (Suppl. 5) (1988) 1118.Google Scholar
  28. 28.
    Kurz, C. C., Marget, W., Harms, K., Bertele, R. M.: Vergleichende Untersuchung mit Ciprofloxacin und Ofloxacin in Kreuzversuch bei Zystischer Fibrose. Fortschritte der Antimikrobiellen und Antineoplastischen Chemotherapie (1987) 6–10, 2107–2113.Google Scholar
  29. 29.
    Alfaham, M., Holt, M. E., Goachild, M. C. Arthropathy in a patient with cystic fibrosis taking ciprofloxacin. Br. Med. J. 295 (1987) 699.Google Scholar
  30. 30.
    Jawad, A. S. M. Cystic fibrosis and drug-induced arthropathy. Br. J. Rheumatol. 2 (1989) 179–180.Google Scholar
  31. 31.
    Schaad, U. B., Wedgwood-Krucko, J., Guenin, K., Buehlmann, U., Kraemer, R. Antipseudomonal therapy in cystic fibrosis: aztreonam and amikacin versus ceftazidime and amikacin administered intravenously followed by oral ciprofloxacin. Eur. J. Clin. Microbiol. Infect. Dis. 10 (1989) 858–865.Google Scholar
  32. 32.
    Bending, J. W. A., Kyle, P. W., Giangrade, P. L. F., Samson, D. M., Azadian, B. S. Two neutropenic patients with multiple resistantPseudomonas aeruginosa septicaemia treated with ciprofloxacin. J. R. Soc. Med. 80 (1987) 316–317.Google Scholar
  33. 33.
    Bannon, J. M., Stuchfield, P. R., Weindling, A. M., Damjanovic, V. Ciprofloxacin in neonatalEnterobacter cloacae septicaemia. Arch. Dis. in Childhood 64 (1989) 1388–1391.Google Scholar
  34. 34.
    Dagan, R., Schlaeffer, F., Einhorn, M. Parenteral fluoroquinolones for the treatment of children with life-threatening infections not responding to other antibiotics. Rev. Infect. Dis. Suppl. 5 (1989) 1117.Google Scholar
  35. 35.
    Koehler, B., Koehler, M., Guzikowska, E.: Ciprofloxacin versus imipenem/cilastatin in severe infections in children. Internatl. Congress for Infections Diseases, Montreal, July 1990, Abstract Nr. 265, p. 102.Google Scholar
  36. 36.
    Isaacs, D., Slack, P. M. E., Wilkinson, A. R., Westwood, A. W. Successful treatment ofPseudomonas ventriculitis with ciprofloxacin. J. Antimicrob. Chemother. 17 (1986) 535–538.Google Scholar
  37. 37.
    Mandal, B., Flegg, P., Dunbar, E., Whale, K., Brennand, J.: Ciprofloxacin in enteric fever. Proceedings 5th MCC Cairo, 1986. Chemotherapie 6 (Suppl. 2) 492–493.Google Scholar
  38. 38.
    Karlsson, L. Tyfoidfall i Boras. Epid-Aktuellt (edited by Statens Bacteriologiska Laboratorium/Sweden) 10, (1990) 4.Google Scholar
  39. 39.
    Martorana, G., Giberti, C., Pizzorno, R., Bonamini, A., Oneto, F., Curotto, A., Soro, O. Treatment of urinary tract infections with ciprofloxacin. Clin. Ther. 5 (1988) 516–520.Google Scholar
  40. 40.
    Lotti, T., Mirone, V., Imbimbo, C., Russo, A. Ciprofloxacin in the treatment of urinary tract infections. J. Int. Med. Res. 15 (1987) 240–244.Google Scholar
  41. 41.
    Humphreys, H., Loveging, A., White, L. O., Williams, E. W. Flavobacterium meningosepticum infection in a 32-day-old child on acute peritoneal dialysis, treated with ciprofloxacin. J. Antimicrob. Chemother. 2 (1989) 292–294.Google Scholar
  42. 42.
    Humphreys, H., Speller, D. C. E. Acute epididymo-orchitis caused byPseudomonas aeruginosa and treated with ciprofloxacin. J. Infect. 19 (1989) 257–261.Google Scholar
  43. 43.
    Chapman, S. T., Speller, D. C. E., Reeves, D. S. Resistance to ciprofloxacin. Lancet ii (1985) 39.Google Scholar
  44. 44.
    Newson, S. W. B., Murphy, P., Warren, R. E., Matthews, J. Clinical studies with ciprofloxacin. 4. MCC, Rhodos, 1985, 415–416.Google Scholar
  45. 45.
    Houwen, R. H. J., Bijleveld, C. M. A., de Vries-Hospers, H. G. Ciprofloxacin for cholangitis after hepatic portoenterostomy. Lancet i (1987) 1367.Google Scholar
  46. 46.
    Pagakrong Lumbiganon, Krisana Pengsan, Tussanee Sookpranee, Vallop Laopalboon, Werachai Cowsuwon: Ciprofloxacin in the treatment of neonatal sepsis due to multiresistant gram-negative enteric bacilli. 2nd Western Pacific Congress on Infectious Diseases and Chemotherapy, Jomtien-Pattaya, Thiland, December 11–14, 1990. Program and Abstract p. 367.Google Scholar
  47. 47.
    Phillips, B. M., David, T. V. Pathogenesis and management of arthropathy in cystic fibrosis. J. Royal Soc. of Med. 79 (Suppl. 12) (1986) 44–50.Google Scholar
  48. 48.
    Adam, D. Use of quinolones in pediatric patients. Rev. Inf. Dis. Suppl. 5 (1989) 1113–1116.Google Scholar
  49. 49.
    Schaad, U. B. Use of quinolones in pediatrics. Eur. J. Clin. Microbiol. Inf. Dis. 4 (1991) 355–360.Google Scholar
  50. 50.
    Fontaine, O. Antibiotics in the management of shigellosis in children: What role for the quinolones? Rev. Inf. Dis. Suppl. 5 (1989) 1145–1150.Google Scholar
  51. 51.
    Cruciani, M., Concia, E., Navarra, A., Perversi, L., Bonetti, F., Arico, M., Nespoli, L. Prophylactic co-trimoxazole versus norfloxacin in neutropenic children — prospective randomized study. Infection 17 (1989) 65–69.Google Scholar
  52. 52.
    Chevais, M., Reinert, P., Rondeau, M. C., Tobelem, R., Albeugres, E., Riant, P., Tillement, J. P. Critical risk/benefit analysis of pefloxacin use in children under 15 years — the problem of arthraglias. Int. J. Clin. Pharmacol. Toxicol. 6 (1987) 306–309.Google Scholar
  53. 53.
    Douidar, S. M., Snodgrass, W. R. Potential role of fluoroquinolones in pediatric infections. Rev. Inf. Dis. 11 (1989) 878–889.Google Scholar
  54. 54.
    Schaad, U., Wedgwood, J.: Use of quinolones in pediatrics. 2nd Western Pacific Congress on Infectious Diseases and Chemotherapy. Jomtien-Pattaya, Thailand, December 11–14, 1990. Program and Abstracts p. 125.Google Scholar
  55. 55.
    Williams, J. D.: Therapeutic possibilities for quinolones use in the future. 2nd Western Pacific Congress on Infectious Diseases and Chemotherapy, Jomtien-Pattaya, Thailand, December 11–14, 1990. Program and Abstracts p. 130.Google Scholar
  56. 56.
    Grenier, B. Use of the new quinolones in cystic fibrosis. Rev. Inf. Dis. 4 (1989) 1245–1252.Google Scholar
  57. 57.
    Cheesbrough, J. S., Ilunga Mwema, F., Green, S. D. R., Tillotson, G. S. Quinolones in children with invasive salmonellosis. Lanceti i (1991) 127.Google Scholar

Copyright information

© MMV Medizin Verlag GmbH München 1991

Authors and Affiliations

  • V. Chyský
    • 1
  • R. Hullmann
    • 1
  • P. Schacht
    • 1
  • K. Kapila
    • 2
  • R. Echols
    • 2
  • G. Arcieri
    • 3
  1. 1.Bayer AG, Pharma ForschungszentrumKlinische Forschung DeutschlandWuppertal 1Germany
  2. 2.Miles Inc., Pharmaceutical Div.West HavenUSA
  3. 3.Miles Inc.SuffernUSA

Personalised recommendations